| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Pritumumab (anti-Vimentin)
CAS:499212-74-7
Package:5mg;10mg Remarks:K14184
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Pritumumab
CAS:499212-74-7
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Pritumumab
CAS:499212-74-7
Purity:95% Package:1mg;1g;100g
|
|
| | Pritumumab Basic information |
| Product Name: | Pritumumab | | Synonyms: | pritumumab;Research Grade Pritumumab(DHC35301);Research Grade Pritumumab;Pritumumab (anti-Vimentin) | | CAS: | 499212-74-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Pritumumab Structure]() |
| | Pritumumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Pritumumab Usage And Synthesis |
| Uses | Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2]. | | in vivo | Pritumumab is effective in preventing tumor growth in nude mice but not in SCID mice[1].
Pritumumab can limit the growth of xenograft glioma tumors in vivo only in the presence of intact cell-mediated immunity[1]. | | References | [1] Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017.
[2] Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95. DOI:10.1016/j.mehy.2013.05.037 |
| | Pritumumab Preparation Products And Raw materials |
|